DE69533900T2 - Substituierte 6(4)-Benzyloxypyrimidine - Google Patents

Substituierte 6(4)-Benzyloxypyrimidine Download PDF

Info

Publication number
DE69533900T2
DE69533900T2 DE69533900T DE69533900T DE69533900T2 DE 69533900 T2 DE69533900 T2 DE 69533900T2 DE 69533900 T DE69533900 T DE 69533900T DE 69533900 T DE69533900 T DE 69533900T DE 69533900 T2 DE69533900 T2 DE 69533900T2
Authority
DE
Germany
Prior art keywords
amino
compound
alkyl
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69533900T
Other languages
German (de)
English (en)
Other versions
DE69533900D1 (de
Inventor
C. Robert Frederick Moschel
E. Anthony Hershey Pegg
M. Eilleen Oak Park Dolan
Mi-Young Anyang-Shi Kyoungki-Do Chae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Penn State Research Foundation
United States Department of Health and Human Services
Original Assignee
Arch Development Corp
Penn State Research Foundation
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp, Penn State Research Foundation, United States Department of Health and Human Services filed Critical Arch Development Corp
Application granted granted Critical
Publication of DE69533900D1 publication Critical patent/DE69533900D1/de
Publication of DE69533900T2 publication Critical patent/DE69533900T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69533900T 1994-08-01 1995-07-31 Substituierte 6(4)-Benzyloxypyrimidine Expired - Fee Related DE69533900T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US283953 1994-08-01
US08/283,953 US5525606A (en) 1994-08-01 1994-08-01 Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines

Publications (2)

Publication Number Publication Date
DE69533900D1 DE69533900D1 (de) 2005-02-03
DE69533900T2 true DE69533900T2 (de) 2005-12-29

Family

ID=23088285

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69533900T Expired - Fee Related DE69533900T2 (de) 1994-08-01 1995-07-31 Substituierte 6(4)-Benzyloxypyrimidine
DE69523462T Expired - Fee Related DE69523462T2 (de) 1994-08-01 1995-07-31 Substituierte o6-benzylguanine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69523462T Expired - Fee Related DE69523462T2 (de) 1994-08-01 1995-07-31 Substituierte o6-benzylguanine

Country Status (10)

Country Link
US (8) US5525606A (cg-RX-API-DMAC7.html)
EP (3) EP0775142B1 (cg-RX-API-DMAC7.html)
JP (2) JP3981407B2 (cg-RX-API-DMAC7.html)
AT (2) ATE286054T1 (cg-RX-API-DMAC7.html)
CA (2) CA2195856C (cg-RX-API-DMAC7.html)
DE (2) DE69533900T2 (cg-RX-API-DMAC7.html)
DK (2) DK1142893T3 (cg-RX-API-DMAC7.html)
ES (2) ES2233513T3 (cg-RX-API-DMAC7.html)
PT (2) PT775142E (cg-RX-API-DMAC7.html)
WO (1) WO1996004281A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043228A (en) * 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP1017394B1 (en) * 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6060458A (en) * 1998-02-13 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use
US6677345B1 (en) * 1998-03-28 2004-01-13 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibitors
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
US8791081B2 (en) * 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002036578A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
BR0207302A (pt) * 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CN100415747C (zh) * 2002-08-08 2008-09-03 记忆药物公司 磷酸二酯酶4抑制剂
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
DE10307928A1 (de) * 2003-02-25 2004-09-16 Faustus Forschungs Cie. Translational Cancer Research Gmbh Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
US20070155752A1 (en) * 2004-01-06 2007-07-05 Government of the United States of America, 2-Amino-o4-substituted pteridines and their use as inactivators of o6-alkylguanine-dna alkyltransferase
PL1746889T3 (pl) * 2004-05-12 2010-01-29 Bayer Cropscience Ag Regulacja wzrostu roślin
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
AU2005282562A1 (en) * 2004-09-08 2006-03-16 Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Beta-glucuronidase cleavable prodrugs of O6-alkylguanine-DNA alkyltransferase inactivators
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
BRPI0609509A2 (pt) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
JP2008539198A (ja) * 2005-04-27 2008-11-13 コヴァリス・バイオサイエンシス・アーゲー O6−アルキルグアニン−dnaアルキルトランスフェラーゼと反応するピリミジン
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
CA2620182A1 (en) * 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質(rap)結合体の投与による肝障害の処置
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
WO2008137207A2 (en) * 2007-05-02 2008-11-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inactivators of o6-alkylguanine-dna alkyltransferase
US8542442B2 (en) 2007-05-07 2013-09-24 Centre Suisse d'Electronique et de Microtechnique SA—Recherche et Developpement Isotropic zero-order diffractive filter
WO2009099650A2 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120270812A1 (en) * 2009-08-24 2012-10-25 Duke University Compositions, methods, and kits for determining an alkyl transferase
CN101850504B (zh) * 2010-05-06 2011-11-16 陕西理工学院 一种用两个步进电机控制主轴运动的振动制孔装置
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
US9775835B2 (en) 2012-08-06 2017-10-03 Sirga Advanced Biopharma, Inc. Small molecule inhibitors of viral protein interactions with human t-RNA
ES2688194T3 (es) * 2014-09-11 2018-10-31 Bristol-Myers Squibb Company Inhibidores de mieloperoxidasa de triazolopirimidina y triazolopiridina de tioéter
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4801710A (en) * 1984-10-26 1989-01-31 Merck & Co., Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
EP0184473A1 (en) * 1984-10-26 1986-06-11 Merck & Co. Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
US5723609A (en) * 1988-03-30 1998-03-03 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl purines
US5091430A (en) * 1990-03-13 1992-02-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services O6 -substituted guanine compounds and methods for depleting O6 -alkylguanine-DNA alkyltransferase levels
US5691307A (en) * 1990-03-13 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services O6 -substituted guanine compositions and methods for depleting O6
US5352669A (en) * 1990-03-13 1994-10-04 The Of The United States Of America As Represented By The Department Of Health And Human Services O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity
EP0489878A1 (en) * 1990-06-29 1992-06-17 Vinamul Ltd. Emulsion polymerisation
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
NZ266527A (en) 1993-06-08 1999-10-28 Cancer Res Campaign Tech Alkylguanine derivatives and pharmaceutical compositions
US6043228A (en) 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
ES2148259T3 (es) 1993-09-22 2000-10-16 Hoechst Ag Pro-profarmacos, su produccion y uso.
US5929046A (en) 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DK0795334T3 (da) 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
AU1406499A (en) 1997-11-13 1999-06-07 Case Western Reserve University Delta-o6-methylguanine-dna methyltransferase gene transfer for o6-benzylguanine and (n,n'-bis(2-chloroethyl)-n-nitrosourea) resistance

Also Published As

Publication number Publication date
DE69523462D1 (de) 2001-11-29
US6333331B1 (en) 2001-12-25
ES2233513T3 (es) 2005-06-16
US5525606A (en) 1996-06-11
US5753668A (en) 1998-05-19
PT775142E (pt) 2002-04-29
CA2632452A1 (en) 1996-02-15
EP0775142B1 (en) 2001-10-24
EP1518854A1 (en) 2005-03-30
EP1142893B1 (en) 2004-12-29
US5916894A (en) 1999-06-29
US20020013299A1 (en) 2002-01-31
DE69533900D1 (de) 2005-02-03
DE69523462T2 (de) 2002-07-11
US6303604B1 (en) 2001-10-16
US6172070B1 (en) 2001-01-09
CA2195856C (en) 2008-09-30
PT1142893E (pt) 2005-04-29
DK0775142T3 (da) 2002-02-18
JP2007077157A (ja) 2007-03-29
ATE207490T1 (de) 2001-11-15
JPH10508288A (ja) 1998-08-18
AU3207995A (en) 1996-03-04
ES2167451T3 (es) 2002-05-16
EP1142893A1 (en) 2001-10-10
US5958932A (en) 1999-09-28
JP3981407B2 (ja) 2007-09-26
CA2195856A1 (en) 1996-02-15
ATE286054T1 (de) 2005-01-15
AU702711B2 (en) 1999-03-04
EP0775142A1 (en) 1997-05-28
US6436945B2 (en) 2002-08-20
WO1996004281A1 (en) 1996-02-15
DK1142893T3 (da) 2005-03-29

Similar Documents

Publication Publication Date Title
DE69523462T2 (de) Substituierte o6-benzylguanine
EP0682027B1 (de) Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DE69202243T2 (de) 2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen.
DE60002969T2 (de) Imidazo[5,1-f][1,2,4]triazinderivate
EP0242851A1 (de) N-(2'-Aminophenyl)-benzamid-Derivate, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung neoplastischer Erkrankungen
DE3146772C2 (de) Verwendung von Xanthogenatverbindungen, neue Xanthogenatverbindungen und ein Verfahren zu ihrer Herstellung
DE2502966A1 (de) Neue derivate von 1,7-dihydro-2h- pyrazolo(4',3' zu 5,6)pyrido(4,3-d)pyrimidin-2,4-(3h)-dionen
DE69832276T2 (de) Medikamentvorstufen der ribonukleotidreduktase-inhibitoren 3-ap und 3-amp
DE3850335T2 (de) Antiretroviraler Castanosperminester.
DE3855520T2 (de) Methode zur Verbesserung des Schlafes
DE2505297A1 (de) Neue 2-arylamino-2-imidazolinderivate und ein verfahren zu deren herstellung
DE68910211T2 (de) Estramustin-ester.
DE69200284T2 (de) Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-Tetrahydropyridinderivaten als freie Radikalfänger.
DE69728536T2 (de) Zubereitungen enthaltend eine Nitronverbindung für die Verwendung bei der Behandlung von Uveitis
DD281596A5 (de) Verfahren zur hersteung antiarrhytmischer mittel
CH668970A5 (de) 5-pyrimidincarboxamide, die fuer die behandlung von leukaemie und tumoren verwendbar sind.
EP0557879A1 (de) 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE68911192T2 (de) Phosphonoalkylpurin-Derivate.
DE2804519C2 (cg-RX-API-DMAC7.html)
EP0167817A1 (de) Neue 8-Alkylthio-2-piperazino-pyrimido[5,4-d]pyrimidine, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19706675A1 (de) Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE68919475T2 (de) Bivalente liganden, wirksam für die blockierung des enzyms acat.
DE60004362T2 (de) Thiazolopyrimidine verwendbar als TNF-Alpha Inhibitoren
LV10618B (en) A novel derivatives of thienothiazine, method for preparing thereof and use
CH634844A5 (de) Verfahren zur herstellung von in 9-stellung substituierten 8-azapurinen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee